AMSTERDAM—Fingolimod at an oral dose of 0.5 mg consistently improved relapse rates, disability, and MRI outcomes compared with placebo or IM interferon beta-1a in all patient subgroups with active relapsing-remitting MS, according to data presented at the ECTRIMS/ACTRIMS 5th Joint Triennial Congress.
Eva Havrdová, PhD, from the Department of Neurology, First Faculty of Medicine, Charles University, Prague, Czech Republic, and colleagues reported the results of post hoc analyses from FREEDOMS and TRANSFORMS in three patient subgroups: 1) patients who received interferon beta in the year before study entry and had equal or more relapses in the year immediately before the study than in the year two years before the study, 2) patients who received interferon beta in the year before study entry and had at least one relapse in the previous year plus at least one gadolinium-enhancing T1 lesion or nine T2 lesions at baseline, or 3) treatment naïve patients with rapidly evolving severe relapsing-remitting MS.
In FREEDOMS, fingolimod 0.5 mg significantly reduced annualized relapse rates compared with placebo in all three subgroups. In TRANSFORMS, fingolimod 0.5 mg significantly reduced annualized relapse rates compared with IM interferon beta-1a in groups 1 and 2. Results in group 3 (n = 27) did not reach statistical significance. In both studies fingolimod reduced the risk of disability progression versus placebo and interferon beta-1a in all subgroups.
The researchers concluded that fingolimod (0.5 mg) improved clinical outcomes compared with placebo or IM interferon beta-1a in patients with relapsing-remitting MS with high disease activity despite previous treatment and in treatment naïve patients with rapidly evolving severe relapsing-remitting MS.
Source – Neurology Review
===========================================================
Remain CURRENT with Multiple Sclerosis news and information
Providing You with MS Views and News, is what we do
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
On the Fourth Wednesday of Each Month
Visit: StuMSradio – With Deanna and Stu
or click : Multiple Sclerosis-UnPlugged
* Call (347) 215-9265 *
To listen, speak with us or speak with a guest
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“MS Views and News” is a 501©(3) Not-for-Profit organization as
recognized by the Internal Revenue Service.
All contributions are tax deductible to the fullest extent allowed by law.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly. .
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews